



#19 B RE  
4-30-02  
P.2.

Atty Dkt 1231.003  
2300-1231.01  
PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on  
10 April 2002.

4/10/02

Date

Susan Lamont

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

SALLBERG et al.

Serial No.: 09/466,035

Group Art Unit: 1632

Filing Date: December 17, 1999

Examiner: P. Paras, Jr.

Title: COMPOSITIONS AND METHODS FOR TREATING  
INTRACELLULAR DISEASES

RECEIVED

RESPONSE TO FINAL OFFICE ACTION

APR 26 2002

Assistant Commissioner for Patents  
Box CPA  
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

This paper is responsive to the Final Office Action mailed on October 10, 2001.

Applicants note that although Box 2A on PTO-326 was not checked, page 5 of the Office Action indicates the Action is final. Submitted herewith is a petition for a three month extension of time and appropriate fee, making a response due on or before April 10, 2002. Accordingly, since this response is timely filed.

COPY OF PAPERS  
ORIGINALLY FILED

I. AMENDMENTS

1. (Twice Amended) A method for generating an immune response against one or more intracellular pathogens within warm-blooded animals, comprising:
  - (a) administering to a warm-blooded animal a gene delivery vehicle comprising a polynucleotide encoding at least one immunogenic portion of an antigen obtained from an intracellular pathogen; and
  - (b) administering to said warm-blooded animal at least one protein which comprises at least one of said immunogenic portion of said antigen, such that an immune response against the intracellular pathogen is generated.
5. (Twice Amended) The method according to claim 4, wherein said viral antigen is obtained from a virus selected from the group consisting of hepatitis, feline immunodeficiency virus (FIV), and human immunodeficiency virus (HIV).
25. (Amended) The method of claim 1, wherein the gene delivery vehicle comprises naked DNA.

Attached hereto is a page titled “Version with markings to show changes made to claims” as well as a currently pending claim set.